我們的所有報告 過濾 日期 2022 2021 2020 2019 2018 分類 Clinical Development Landscape in Asia Pacific Dermatology Gene Therapy Infectious Disease Rare Disease Regulatory Haematology Immunology Liver Disease Oncology Metabolic Disorders 2023/3/3 報告 急性骨髓性白血病 (AML) - 全球臨床試驗概況 - 著重於亞太地區。 2020 年亞太地區約有 46,000 AML 病例，其中中國、印度和日本佔全球 40% 的病例。 下載 2023/2/20 報告 類風溼性關節炎 - 全球臨床試驗概況 - 著重於亞太地區 印度與中國的類風溼性關節炎盛行率最高，分別有 1 千萬及 5 百萬例，且觀察到東亞的年齡標準化發生率和盛行率增加速度最快。 下載 2023/1/19 報告 阿茲海默症 (AD) - 亞太地區 - 臨床試驗概況 阿茲海默症是失智症最常見的病因，並且截至 2030 年，亞太地區的病例預計將佔全球所有失智症病例的一半以上。 下載 2023/1/9 報告 Idiopathic Pulmonary Fibrosis - Asia Pacific – Clinical Trial Landscape The global burden of IPF is expected to rise, due to the rapidly aging population of Asia Pacific region, with South Korea, in particular, having the highest incidence and prevalence rates of IPF. 下載 2022/12/16 報告 慢性阻塞性肺病 (COPD) - 亞太地區 - 臨床試驗概況 並排顯示文字：2019 年亞太地區 COPD 盛行率達 13.5%，超過全球平均值，其中最高盛行率出現在中國大陸。直到今日，此地區的疾病負擔和死亡率明顯高出西方國家，顯示這個趨勢仍在不斷攀升。 下載 2022/12/8 報告 花生過敏 – 亞太地區 – 臨床試驗前景 與西方類似，澳洲在亞太地區的花生過敏率最高，影響約 3% 的兒童。 下載 2022/11/25 報告 青光眼 – 亞太地區 – 臨床試驗前景 由於人口基數龐大且高齡化，亞洲佔估計全球青光眼病例的 60% 以上。 下載 2022/11/18 報告 Diabetic Retinopathy Asia Pacific – Clinical Trial Landscape Asia-Pacific region accounts for 51% of all blindness cases and 56% of cases of visual impairment worldwide due to Diabetic Retinopathy 下載 2022/10/12 報告 陣發性夜間血紅素尿症 (Paroxysmal nocturnal hemoglobinuria，PNH) – 亞太地區 – 臨床試驗狀 況。 根據估計，西方地區國家每年每百萬人有 1- 2 起病例患有 PNH，而亞洲地區每年每百萬人約 10 起病例，其中又以中國和印度的 PNH 病例最多。 下載 2022/10/10 報告 C3G 腎絲球病變 (Glomerulopathy) – 亞太地 區 – 臨床試驗狀況 1990 年起至 2019 年間，亞洲地區腎絲球腎 炎 (Glomerulonephritis) 病症的年齡標準化發生率和 盛行率增加幅度遠勝西方地區，特別是南亞地區。 下載 2022/9/29 報告 膽管癌 (Cholangiocarcinoma) 亞太地區 – 臨床 試驗狀況 與世界各地相比，亞洲地區膽管癌盛行率顯著較 高，其中以中國、南韓、泰國與台灣的發生率最 高。 收購及整合長期經營的全方位服務 CRO 合作夥 伴之後，Novotech 現在能為全美國提供服務。 下載 2022/9/27 報告 亞太地區潰瘍性結腸炎 - 臨床試驗概況 過去 40 年來，亞洲的 UC 發病率和盛行率已快速增加， 尤其是在澳洲和日本 下載 2022/9/1 報告 亞太地區的非酒精性脂肪肝炎 (NASH) —臨床試驗現況 摘要——由於亞太地區老齡人口佔全球比例較高，並且相較於西方國家，亞太地區 NASH 盛行率較高 (~60%)，尤其是南亞國家，因此預計全球 NASH 負擔將會提高。 下載 2022/9/1 報告 亞太地區的困難梭狀芽孢桿菌感染症 (CDI) —臨床試驗現況 2019 年，亞洲地區困難梭狀芽孢桿菌感染症佔全球近 15% 的整體盛行率及近 10% 的死亡率。 下載 2022/8/22 報告 Diffuse large b-cell Lymphoma – Asia Pacific – Clinical trial landscape Asia accounted for nearly 70% of the global incidence of DLBCL in 2020, with Mainland China, India, and Japan contributing to a third of all DLBCL cases worldwide. 下載 2022/8/2 報告 Brain/central nervous System (cns) tumors – Asia pacific – clinical Trial landscape Asia accounted for more than 50% of the global incidence of brain and CSN tumor in 2020, with Mainland China, India, and Japan contributing to majority of the cases. 下載 2022/7/28 報告 Psoriasis - Asia Pacific –Clinical Trial Landscape Of the approximately 30 million adult Psoriasis cases that were prevalent globally in 2017, the highest prevalences were found in the Asian region particularly India, Mainland China, and Japan. 下載 2022/7/27 報告 Solid tumors - Asia Pacific – Clinical trial Landscape There were over 8.2 million new cases and over 5 million deaths due to solid cancers in Asia, with the region accounting for half of the new cancer cases and 60% of the world’s deaths in 2020. 下載 2022/7/13 報告 Multiple myeloma - Asia pacific – clinical Trial landscape Multiple myeloma cases are increasing in Asia, with the region currently contributing to more than 35% of the projected global incidence, with China, India, and Japan comprising more than a quarter 下載 2022/7/13 報告 Covid-19 - asia pacific – Clinical trial landscape Asia Pacific accounts for around 20% of the total COVID-19 cases reported globally with Taiwan, Australia, Japan, and South Korea reporting the highest number of new cases of COVID-19 in the region 下載 2022/6/22 報告 Parkinson’s disease - Asia pacific – clinical Trial landscape Due to the presence of half of the world’s aging population and a high population growth rate in APAC, the global burden of Parkinson's Disease is expected to rise, with China, Japan, and India col 下載 2022/6/15 報告 Acute pancreatitis – Asia pacific – clinical Trial landscape Owing to its huge, aged population base, Asia accounts for over 55% of the estimated global incidence of Acute pancreatitis, with China, Japan, and India collectively contributing to over a quarter 下載 2022/6/15 報告 Chronic pain - Asia pacific – clinical Trial landscape In Asia Pacific, Chronic Pain affects more than half of the population, with China and India together contributing close to 700 million cases. 下載 2022/5/26 報告 Follicular lymphoma - Asia pacific - clinical Trial landscape Owing to its large population base, Asia may account for over 40% of the estimated global incidence of Follicular Lymphoma, with China, Japan and India collectively contributing to over a quarter o 下載 2022/5/26 報告 Atopic dermatitis Asia has been witnessing increasing levels of Atopic Dermatitis (AD) over the previous few decades, with the Paediatric AD prevalence rates in various Asian ethnicities reaching as high as 20%. 下載 2022/5/24 報告 Renal Cell Carcinoma Owing to its large population base, Asia accounts for over 35% of the estimated global incidence of Renal cell carcinoma, with China, Japan, and India collectively contributing to over a quarter of 下載 2022/3/31 報告 Triple negative breast Cancer With a high population density and over 45% of the global breast cancer incidence, Asia is expected to account for more than half of all TNBC cases, with a large TNBC patient pool, particularly in 下載 2022/3/17 報告 Disease report - CKD - APAC - CT Landscape Diabetes and hypertension are expected to drive the global prevalence of CKD, with much of this increasing burden observed in Asian locations of China and India. 下載 2022/3/14 報告 Hepatitis B - Asia Pacific - Clinical trials Landscape The Asia-Pacific with an intermediate to high prevalence, represents three-quarters of chronic hepatitis B (CHB)-positive subjects worldwide. 下載 2022/2/24 報告 Small cell lung cancer Each year, there are over 300,000 new cases of Small Cell Lung Cancer globally, with Asia accounting for nearly 60% of the cases. 下載 2022/2/3 報告 Prostate cancer Asia ranks second in Prostate cancer incidence accounting for over a quarter of the global incident cases and has the world’s highest number of deaths due to Prostate cancer in 2020. 下載 2022/1/21 報告 Bladder cancer Asia accounted for over a third of the global bladder cancer incidence with over 200,00 newly diagnosed cases, with China having a higher prevalence of bladder cancer in 2020. 下載 2022/1/21 報告 Thyroid cancer Asia accounted for almost 60% of the global incidence, mortality and five-year prevalence in 2020, with the highest incidence rates found in Australia and Eastern Asia for both sexes. 下載 2021/12/17 報告 Cervical cancer Asia pacific Clinical trial landscape Asia accounts for almost 60% of the global incidence of cervical cancer, with India and China together contributing to more than a third of all cases and deaths. 下載 2021/12/17 報告 Pancreatic cancer Clinical trials landscape Asia pacific The incidence of pancreatic cancer is rising in Asia-Pacific, with the region accounting for about half of new cases in 2020. 下載 2021/12/17 報告 Gastric cancer Clinical trial landscape Asia-pacific Nearly 75% of the new gastric cancer cases in the world are concentrated in Asia, with China showing the highest incidence and mortality. 下載 2021/11/29 報告 Colorectal cancer clinical trials landscape asia pacific The incidence of colorectal cancer cases is rapidly growing in Asia-Pacific and the region now accounts for more than half of all new cases diagnosed globally. 下載 2021/11/29 報告 Lung cancer (nsclc) clinical trials landscape asia pacific In Asia, lung cancer ranks as the most prevalent cancer and the primary cause of mortality, with the region accounting for almost 60% of the global incidence of lung cancer. 下載 2021/11/3 報告 Esophageal cancer – Clinical trials landscape – Asia pacific In Asia, EC is the sixth most common cancer, with the region constituting almost 80% of the new EC cases globally. The highest standardized incidence rate has been observed in East Asia. 下載 2021/10/14 報告 Clinical trial landscape Of cll in asia-pacific CLL is one of the most common forms of leukaemia, with the Asia Pacific region showing increasing incidence. China and South Korea are among the Asian locations showing the greatest incidence. 下載 2021/10/12 報告 Clinical trial landscape of Liver cancer in asia pacific According to the Globocan 2020 report, liver cancer is the fourth most frequent cancer in Asia, with the region accounting for over 70% of all new liver cancer cases worldwide. 下載 2021/9/17 報告 Clinical trial landscape of diabetes (type 2) in asia-pacific Diabetes, which is endemic in most Western countries, is now seeing a surge in developing nations across Asia due to aging, urbanization, and changing dietary habits. 下載 2021/9/17 報告 Clinical trial landscape of endometrial cancer in asia-pacific In 2020, Globocan reported over 400,000 new corpus uteri cases, with Asia accounting for about 40% of these new cases. 下載 2021/8/27 報告 Clinical trial landscape of B-cell lymphoma in asia-pacific Diffuse Large B-Cell Lymphoma (DLBCL) is the most common and the most aggressive subtype constituting nearly 70% of B-Cell Lymphomas in Asia. 下載 2021/8/20 報告 Clinical trial landscape of t-cell lymphomas in asia-pacific T-cell lymphomas (TCLs) are types of non-Hodgkin’s lymphoma (NHL) that affect T lymphocytes. 下載 2021/8/18 報告 Cystic fibrosis-Clinical Trials Landscape-APAC Cystic fibrosis is a rare autosomal recessive disease which primarily affects the lungs and digestive system due to a malfunction in the exocrine system responsible for producing saliva, sweat, tea 下載 2021/2/15 報告 AML Landscape in Asia-Pacific AML is the most common form of leukemia in adults, accounting for approximately a third of all leukemia cases worldwide. 下載 2021/2/15 報告 Ovarian Cancer Landscape in Asia-Pacific Ovarian cancer is the 7th most common cancer and 8th leading cause of cancer mortality among women globally. 下載 2021/2/15 報告 NHL Landscape in Asia-Pacific Lymphoma, including Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL), is one of the most common cancers worldwide. 下載 2021/2/15 報告 Melanoma Landscape in Asia-Pacific Cancer of the skin is by far the most common of all cancers. Melanoma accounts for only about 1% of skin cancers but causes a large majority of skin cancer deaths. 下載 2021/2/15 報告 H&N Cancer Landscape in Asia-Pacific Head and neck cancer (HNC) is the sixth most common cancer globally, with the highest incidence being observed in the Asia region. 下載 2021/2/15 報告 Breast Cancer Landscape in Asia-Pacific Breast cancer is the most frequent cancer, impacting 2.1 million patients each year, and causes the greatest number of cancer-related deaths. 下載 2020/2/28 報告 澳洲臨床試驗的法規要求 憑藉簡化的法規環境，包括對 IND 無任何規定，以及在臨床研究支出上，有支持研發的政府退還金高達 43.5% ，讓澳洲成為早期臨床試驗的首選目的地。 過去幾年來，澳洲的臨床試驗案件數穩定成長，在 2016 年至 2018 年期間每年成長超過 10%。 下載 2020/2/5 報告 Accelerating Genetic Therapy Clinical Trials in Asia-Pacific A growing number of biotechnology companies, both in the West and in Asia, are specializing in gene therapies and other regenerative treatments boosted by the approval of the first genetic therapy 下載 2020/2/4 報告 Accelerating Immunotherapy Clinical Trials in Asia-Pacific Over 600 sites across Asia-Pacific have been involved in the clinical development of now approved IO drugs, and hundreds more are experienced in managing clinical trials with immunotherapies for bo 下載 2019/12/1 報告 加速亞太區的孤兒藥物試驗 近年來，我們觀察到前所未有的努力可見於孤兒藥的臨床開發上。事實上，在 2018 年，美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 批准的大多數的新藥都是孤兒藥。 本報告的目的，是要描述孤兒藥的發展現況，並解釋在全球局勢中，亞洲地區的地位是如何演進的。 下載 載入更多
全域
中國
